Related Experiment Video
Updated: Apr 11, 2026
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
8.1K
Abstract:
The small molecule BDA-366 selectively inhibits BCL2, converting it to a cell death inducer.
Insights
The small molecule BDA-366 selectively inhibits BCL2 (B-cell lymphoma 2), transforming it into a potent cell death inducer. This discovery offers a novel therapeutic strategy for targeting BCL2-related conditions.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- BCL2 is a key anti-apoptotic protein.
- Dysregulation of BCL2 is implicated in various cancers.
- Targeting BCL2 is a promising cancer therapeutic strategy.
Purpose of the Study:
- To investigate the effects of the small molecule BDA-366.
- To determine if BDA-366 can selectively inhibit BCL2.
- To explore BDA-366's potential as a cell death inducer.
Main Methods:
- In vitro assays to assess BCL2 inhibition.
- Cell-based assays to evaluate cell death induction.
- Molecular mechanism studies.
Main Results:
- BDA-366 demonstrated selective inhibition of BCL2.
- BDA-366 effectively induced cell death in relevant models.
- The molecule's mechanism involves converting BCL2 into a pro-apoptotic factor.
Conclusions:
- BDA-366 is a novel BCL2 inhibitor with cell death-inducing properties.
- This molecule represents a potential new therapeutic agent for BCL2-driven diseases.
- Further research into BDA-366 is warranted for clinical development.
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:34Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
01:31The Intrinsic Apoptotic Pathway
9.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K